• PDF / 172,287 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 79 Downloads / 157 Views

DOWNLOAD

REPORT

---

S

Adrenal insufficiency: 2 case reports In a case report, a 67-year-old man and an approximately 53-year-old man were described, who developed adrenal insufficiency (AI) during treatment with abiraterone and prednisone for metastatic prostate cancer [MPC; routes not stated]. Case 1: The 67-year-old man, who had stage 4 MPC, Crohn’s disease and bilateral ureteral stents, had been receiving abiraterone [Zytiga] 1 g/day and prednisone 5 mg/day. Previously, he had been admitted to the ICU in septic shock from a urinary tract infection, and he had received a stress dose corticosteroid coverage [prednisone; dosage not stated] on admission to the ICU. He had recovered with unspecified antibiotic therapy and bilateral ureteral stent exchange, and he was discharged after 7 days. Approximately 2 weeks after discharge, he experienced 4 days of progressive fatigue and profound dyspnoea on exertion, and he was readmitted. Also, he experienced difficulty in ambulating more than a few steps. Central obesity and proximal lower extremity muscle weakness were observed on physical examination. He received physical therapy; however, based on the ongoing therapy with abiraterone and prednisone and the lack of improvement with physical therapy, AI was suspected. Following the discontinuation of prednisone for 24h, standard cosyntropin stimulation test showed a baseline morning serum cortisol and ACTH levels of 2.5 µg/dL and 187 pg/mL, respectively. Also, laboratory tests revealed low levels of PB-008 [dehydroepiandrosterone sulfate], hydroxyprogesterone [17-hydroxyprogesterone] and 17-hydroxypregnenolone, while the levels of progesterone, corticosterone and aldosterone were elevated. Subsequently, the dose of prednisone was increased to 20 mg/day for 4 days, during which he exhibited a marked improvement in the symptoms. Then, he was discharged home, and he continued to improve with prednisone 5mg twice daily. However further weaning led to the recurrence of symptoms. On repeat biochemical testing while off prednisone for 24h, morning serum cortisol was noted to have remained low at 1.4 µg/dL. These findings confirmed the diagnosis AI secondary to abiraterone and prednisone [durations of treatments to reaction onset not stated]. He continued to receive prednisone 5mg twice a day at the time of the report. Case 2: The man was diagnosed with metastatic adenocarcinoma of the prostate at the age of 51 years in May 2017. He had been treated with bicalutamide [Casodex], leuprorelin [leuprolide; Lupron], docetaxel, rilimogenegalvacirepvec-rilimogene-glafolivec [Prostvac], durvalumab [duravalamab] and olaparib until December 2018. Durvalumab and olaparib were discontinued due to the progressive metastatic disease in the bone and lung, and he started receiving abiraterone [Zytiga] 1,000mg and prednisone 5mg twice daily in January 2019. However, within 4 days of the initiation of the abiraterone therapy, he experienced muscle cramping, fatigue and malaise. Also, he gained 10 Lbs within 1 week, and he developed pitting oedema of the legs. These s